Program
SAR447971
A development code.
In Sanofi's pipeline, IRAK4 degrader
. Its studies are mostly in Hidradenitis, led by Sanofi.
Furthest: phase 1, since May 22, 20261 company-led study, 1 open or runningNext primary completion: Apr 17, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 1since May 22, 2026 | May 22, 2026 | Apr 17, 2028phase 1 · NCT07629336 |
- Named in Sanofi’s own pipeline as
SAR447971
, phase 1, as of Sep 30, 2026 (source).
Also a collaborator on its studies: kymera-therapeutics-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2026First study: phase 1 study in HidradenitisFirst studyNCT07629336 · 122 planned · Netherlands
Ahead
- Apr 17, 2028Primary completion: phase 1 study in HidradenitisNCT07629336
TargetBeta
“IRAK4 degrader”the company's pipeline, read by Claude · source
Other programs on IRAK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| emavusertibrule | curis-inc | phase 2 | 3 |
| IRAK4 Inhibitor AZD2962rule | AstraZeneca | phase 1 | 1 |
| ARD-885rule | artivila-shenzhen-innovation-center-ltd | phase 1 | 1 |
| HPB-092rule | hangzhou-polymed-biopharmaceuticals-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07629336Hidradenitis · Netherlands | 1 | Recruiting | Apr 17, 2028 | 122 |
How it is read
Names in the registry
- “SAR447971”, 1 entry
Codes read as this program: SAR447971.
Conditions, from the studies’ own filings
- Hidradenitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.